Abbott Laboratories Stock Forecast for 2022 - 2025 - 2030
Updated on 05/24/2022
Abbott Laboratories's stock price reaches the average target of $140.00 by 2023 as expected recently by nineteen notable experts, there would be a potential upside of approximately 23.06% from the last closing price in May, 2022. This possible increase is based on a high estimate of $151.00 and a low estimate of $104.00. If you are interested in ABT stock, it is important to also consider its competitors.
23.06% Upside
Abbott Laboratories Fair Value Forecast for 2022 - 2025 - 2030
In the last three years, Abbott Laboratories's Fair Value has grown by 80.9%, rising from $75.77 to $137.08. For the following year, the 22.00 analysts predict that ABT's Fair Value will drop by 6.72%, reaching $242.06. Over the next nine years, experts predict that Abbott Laboratories's Fair Value will grow at a rate of 76.59%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
5
|
$305.96 | $281.95 | 4.92% | 12 |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
3
|
£104.94 | £136.08 | 39% | 13 |
| DHR Stock Forecast | Danaher | Outperform |
5
|
$252.00 | $339.17 | 32.94% | 7 |
| GSK Stock Forecast | GlaxoSmithKline | Outperform |
1
|
£17.64 | £16.08 | 2.04% | 11 |
| AMAT Stock Forecast | Applied Materials | Outperform |
7
|
$106.59 | $161.48 | 34.63% | 2 |
Abbott Laboratories Revenue Forecast for 2022 - 2025 - 2030
In the last three years, Abbott Laboratories's Revenue has grown by 40.87%, rising from $30.58B to $43.08B. For the following year, the 20.00 analysts predict that ABT's Revenue will drop by 3.35%, reaching $61.87B. Over the next nine years, experts predict that Abbott Laboratories's Revenue will grow at a rate of 43.62%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| CSL Stock Forecast | CSL | Outperform |
4
|
$266.28 | $228.01 | -14.01% | 10 |
| MMM Stock Forecast | 3M | Hold |
5
|
$145.75 | $188.41 | 9.98% | 17 |
| BDX Stock Forecast | Becton, Dickinson and | Outperform |
5
|
$257.45 | $270.20 | 10.7% | 3 |
Abbott Laboratories Dividend per Share Forecast for 2022 - 2025 - 2030
In the past three years, Abbott Laboratories's DPS has seen significant growth, rising from $1.16 to $1.82 – a growth of 56.9%. In the following year, the 10.00 analysts surveyed believe that ABT's DPS will decrease by 0.55%, reaching a dismal $4.15. For the next nine years, the forecast is for DPS to grow by 128.26%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| BAYN Stock Forecast | Bayer | Outperform |
5
|
63.29€ | 67.79€ | 20.08% | 14 |
| CL Stock Forecast | Colgate-Palmolive | Hold |
5
|
$78.12 | $84.90 | 4.97% | 9 |
| EW Stock Forecast | Edwards Lifesciences | Outperform |
5
|
$94.54 | $127.85 | 37.51% | 19 |
Abbott Laboratories Free Cash Flow Forecast for 2022 - 2025 - 2030
Abbott Laboratories's Free Cash Flow has seen impressive growth in the last three years, rising from $4.91B to $8.65B – a growth of 76.27%. In the next year, analysts believe that Free Cash Flow will reach an unimpressive $9.29B – an increase of 7.42%. For the next nine years, the forecast is for Free Cash Flow to grow by 24.85%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| BSX Stock Forecast | Boston Scientific | Outperform |
4
|
$40.15 | $49.85 | 24.53% | 23 |
| GIS Stock Forecast | General Mills | Hold |
2
|
$69.14 | $67.53 | -1.65% | 18 |
| 4568 Stock Forecast | Daiichi Sankyo Company | Outperform |
2
|
¥2.83k | ¥0.00 | 36.07% | 0 |
Abbott Laboratories Net Income Forecast for 2022 - 2025 - 2030
Abbott Laboratories's Net Income has seen astonishing growth in the last three years, rising from $2.37B to $7.07B – a growth of 198.61%. In the next year, analysts believe that Net Income will reach a reasonable $8.64B – an increase of 22.21%. For the next nine years, experts predict that Abbott Laboratories's Net Income will grow at a rate of 131.06%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| BAX Stock Forecast | Baxter International | Outperform |
5
|
$73.90 | $92.47 | 21.79% | 3 |
| A Stock Forecast | Agilent Technologies | Outperform |
7
|
$124.41 | $172.40 | 28.61% | 2 |
| BN Stock Forecast | Danone | Hold |
4
|
54.87€ | 62.59€ | 2.06% | 18 |
Abbott Laboratories EBITDA Forecast for 2022 - 2025 - 2030
In the past three years, Abbott Laboratories's EBITDA has grown by 79.26%, rising from $7.12B to $12.76B. Over the next nine years, experts believe that ABT's EBITDA will grow at a rate of 43.22%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| EDF Stock Forecast | Electricité de France | Outperform |
4
|
8.41€ | 14.68€ | 13.67% | 9 |
| 4503 Stock Forecast | Astellas Pharma | Outperform |
2
|
¥1.80k | ¥0.00 | 33.33% | 0 |
| DXCM Stock Forecast | DexCom | Buy |
0
|
$288.13 | $560.79 | 82.21% | 3 |
Abbott Laboratories EBIT Forecast for 2022 - 2025 - 2030
In the last three years, Abbott Laboratories's EBIT has seen significant growth, surging from $3.84B to $9.22B – an increase of 140.18%. In the next year, analysts predict that EBIT will jump to $10.33B – up 12.07% from the current level. Looking ahead to nine years, experts forecast that EBIT will grow by 112.71%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| 7751 Stock Forecast | Canon | Hold |
2
|
¥2.64k | ¥0.00 | 14.9% | 0 |
| CHD Stock Forecast | Church & Dwight | Hold |
5
|
$90.43 | $88.52 | 9.48% | 9 |
| CAH Stock Forecast | Cardinal Health | Hold |
5
|
$57.11 | $57.23 | 1.56% | 4 |
Abbott Laboratories EPS Price Prediction Forecast for 2022 - 2025 - 2030
In the last three years, Abbott Laboratories's EPS has grown by 80.9%, rising from $2.88 to $5.21. For the following year, the 22.00 analysts predict that ABT's EPS will drop by 6.72%, reaching $9.20. Over the next nine years, experts predict that Abbott Laboratories's EPS will grow at a rate of 76.59%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| BIO Stock Forecast | Bio-Rad Laboratories | Outperform |
7
|
$518.73 | $701.33 | 34.94% | 2 |
| TECH Stock Forecast | Bio-Techne | Outperform |
3
|
$357.17 | $528.73 | 39.99% | 11 |
| 4523 Stock Forecast | Eisai | Hold |
0
|
¥6.85k | ¥0.00 | -3.61% | 0 |